Speakers

Eugenia Ong received her PhD in Integrated Biology and Medicine from Duke-NUS Medical School. She completed her postdoctoral training at Experimental Therapeutics Centre, A*STAR where she led pre-clinical studies for a pan-serotype monoclonal antibody (mAb) against dengue virus (DENV), VIS513, developed by Visterra Inc.

She is currently Principal Research Scientist of the Viral Research and Experimental Medicine Centre @ SingHealth Duke-NUS Academic Medical Centre (ViREMiCS), an ISO 15189 compliant laboratory that brings the latest molecular tools to bear for both industry and academia to accelerate translation of new vaccines and therapeutics from pre-clinical development to clinical trials.